The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer
Open accessAbstract
Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance. This study revealed that diminished MEIS1 expression was detected in CRC and harmed the survival of CRC patients. MEIS1 impaired CRC cell viabilities and tumor growth in mice and enhanced CRC cell sensitivity to oxaliplatin by preventing DNA damage repair. Mechanistically, oxaliplatin resistance following MEIS1 suppression was critically dependent on enhanced FEN1 expression. Subsequently, we confirmed that EZH2-DNMT3a was assisted by lncRNA ELFN1-AS1 in locating the promoter of MEIS1 to suppress MEIS1 transcription epigenetically. Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance. This study highlights the potential of therapeutics targeting ELFN1-AS1 and EZH2 in cell survival and oxaliplatin resistance, based on their controlling of MEIS1 expression, which deserve further verification as a prospective therapeutic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Targeting EZH2 may also be an effective strategy to overcome oxaliplatin resistance, since EZH2 was shown to promote oxaliplatin resistance in CRC cells, while EZH2 inhibitor suppressed tumor growth and sensitized CRC cells to oxaliplatin [172,173].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
lincRNAs: Genomics, Evolution, and Mechanisms
Ulitsky, I., & Bartel, D. P. (2013) · Cell · doi:10.1016/j.cell.2013.06.020 · Cited by 2,608
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 1×
“Among them, GSK126 with a highly selective and inhibitory effect on EZN2 was investigated further in this study.(25) GSK126 did increased the protein level of MEIS1 in HCT116/L-OHP cells in a dose-dependent manner (Supplementary Fig.”
BackgroundKogo, R., Shimamura, T., Mimori, K., Kawahara, K., Imoto, S., Sudo, T., Tanaka, F., Shibata, K., Suzuki, A., Komune, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1021 · Cited by 1,238
Xiang, J.-F., Yin, Q.-F., Chen, T., Zhang, Y., Zhang, X.-O., Wu, Z., Zhang, S., Wang, H.-B., Ge, J., Lu, X., et al. (2014) · Cell Research · doi:10.1038/cr.2014.35 · Cited by 726
DNA Methyltransferases, DNA Damage Repair, and Cancer
Jin, B., & Robertson, K. D. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-9967-2_1 · Cited by 519
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
Van Cutsem, E., Nordlinger, B., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq222 · Cited by 479
Cited by
Targeting epigenetic regulators to overcome drug resistance in cancers
Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 311
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
Huang, Y., Yang, W., Yang, L., Wang, T., Li, C., Yu, J., Zhang, P., Yin, Y., Li, R., & Tao, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-41490-x · Cited by 85
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Targeting EZH2 may also be an effective strategy to overcome oxaliplatin resistance, since EZH2 was shown to promote oxaliplatin resistance in CRC cells, while EZH2 inhibitor suppressed tumor growth and sensitized CRC cells to oxaliplatin [172,173].”
LncRNAs and the cancer epigenome: Mechanisms and therapeutic potential
Nadhan, R., Isidoro, C., Song, Y. S., & Dhanasekaran, D. N. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217297 · Cited by 58
Metadata
- Authors
- Li, Y., Gan, Y., Liu, J., Li, J., Zhou, Z., Tian, R., Sun, R., Liu, J., Xiao, Q., Li, Y., Lu, P., Peng, Y., Peng, Y., Shu, G., & Yin, G.
- Affiliations
- Central South University (CN)
- Corresponding author
- Yin, Gang
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2022-03-30
- Volume
- 7
- Issue
- 1
- Pages
- 87-87
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC8964798
- OpenAlex
- W4220837638
- Cited by
- 153
- References
- 53
- Citations by year
- 2026: 19 · 2025: 38 · 2024: 50 · 2023: 36 · 2022: 10
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82173376)
- Key Project of Hunan Province
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- MEIS1, EZH2, DNMT3A, oxaliplatin resistance, colorectal cancer, FEN1, DNA repair, long non-coding RNA, transcriptional repression, GSK126, antisense oligonucleotides, tumor growth
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Oxaliplatin, Animals, Cell Transformation, Neoplastic, Humans, Colorectal Neoplasms, Down-Regulation, Cell Proliferation, Mice, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. https://app.cochat.ai/papers/10.1038/s41392-022-00902-6
- The paper
- Li, Y., Gan, Y., Liu, J., Li, J., Zhou, Z., Tian, R., Sun, R., Liu, J., Xiao, Q., Li, Y., Lu, P., Peng, Y., Peng, Y., Shu, G., & Yin, G. (2022). Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-00902-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.